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Glucagon-like peptide-1 receptor (GLP-1R) activa-
tion within the nucleus tractus solitarius (NTS)
suppresses food intake and body weight (BW), but
the intracellular signals mediating these effects are
unknown. Here, hindbrain (fourth i.c.v.) GLP-1R acti-
vation by Exendin-4 (Ex-4) increased PKA andMAPK
activity and decreased phosphorylation of AMPK in
NTS. PKA and MAPK signaling contribute to food
intake and BW suppression by Ex-4, as inhibitors
RpcAMP and U0126 (fourth i.c.v.), respectively,
attenuated Ex-4’s effects. Hindbrain GLP-1R activa-
tion inhibited feeding by reducing meal number, not
meal size. This effect was attenuatedwith stimulation
of AMPK activity by AICAR (fourth i.c.v.). The PKA,
MAPK, and AMPK signaling responses by Ex-4
were present in immortalized GLP-1R-expressing
neurons (GT1-7). In conclusion, hindbrain GLP-1R
activation suppresses food intake and BW through
coordinated PKA-mediated suppression of AMPK
and activation of MAPK. Pharmacotherapies target-
ing these signaling pathways, which mediate
intake-suppressive effects of CNS GLP-1R activa-
tion, may prove efficacious in treating obesity.
INTRODUCTION
Glucagon-like peptide-1 (GLP-1), a neuropeptide endogenously
produced from ‘‘L’’ cells in the gastrointestinal tract and centrally
in neurons of the nucleus tractus solitarius (NTS), plays an impor-
tant role in glycemic regulation and energy balance (for review,
see Hayes et al., 2010a; Holst, 2007). Accumulating clinical and
basic science data suggest that pharmacotherapies targeting
the GLP-1 system are ameliorative not only for type 2 diabetes
Mellitus (T2DM), but for obesity as well (Lovshin and Drucker,
2009). Interestingly, exogenous activation of either peripheral or
central GLP-1 receptors (GLP-1Rs) produces a comparable
profile of physiological responses that include enhanced320 Cell Metabolism 13, 320–330, March 2, 2011 ª2011 Elsevier Inc.glucose-stimulated insulin secretion (Komatsu et al., 1989),
inhibition of gastric emptying (Hayes et al., 2008b; Imeryuz
et al., 1997; Wettergren et al., 1993), and inhibition of food intake
(Chelikani et al., 2005; Gutzwiller et al., 1999; Hayes et al., 2008b,
2009a; Kinzig et al., 2002; Moran et al., 1996; Turton et al., 1996).
Althoughmuch is knownabout themechanismsbywhich periph-
eral GLP-1R activation engages these physiological responses,
the relevant central GLP-1R populations and their projections,
as well as the intracellular signaling cascades that mediate the
food intake inhibitory effects of central GLP-1R-activation, have
received considerably less attention.
GLP-1Rs are widely expressed throughout the central nervous
system (CNS) inmany sites relevant to energybalance regulation,
including nuclei in the caudal brainstem (NTS; parabrachial
nucleus), hypothalamus (lateral hypothalamus, LH; paraventricu-
lar hypothalamus, PVH), and basal forebrain (bed nucleus of stria
terminalis; central nucleus of the amygdala) (Goke et al., 1995;
Larsen et al., 1997; Merchenthaler et al., 1999). Recent reports
highlight the importance of hindbrain GLP-1R-expressing nuclei
in the control of food intake and body weight (BW) (Hayes et al.,
2008b, 2009a; Kinzig et al., 2002). Specifically, the endogenous
activation of GLP-1R within the caudal medial-subnucleus of
the NTS (mNTS) was shown to contribute to the normal control
of food intake by mediating satiation signaling that arises from
mechanical distension of the stomach (Hayes et al., 2009a).
The intracellular signaling pathways within GLP-1R-expressing
NTS neurons that mediate the food intake and BW-suppressive
effects of CNS GLP-1 action have not been characterized.
In pancreatic b cells, GLP-1R activation leads to stimulation of
adenylate cyclase, elevated cAMP, and subsequent activation of
protein kinase A (PKA) (Gomez et al., 2002; Perfetti and Merkel,
2000). Given that PKA signaling is upstream of many signaling
pathways implicated in energy balance regulation, it is likely
that the intake-suppressive effects of hindbrain GLP-1R activa-
tion involve endemic signaling pathways that alter intracellular
Ca2+ influx and/or longer-term alterations in gene transcription
and protein synthesis to integrate various anorectic signals.
Whether the intake-suppressive effects of hindbrain GLP-1R
activation are indeed dependent upon an increase in PKA activity
within GLP-1R-expressing NTS neurons remains to be tested.
In neurons, elevated cAMP levels increase phosphorylation of
the p44/42 mitogen-activated protein kinase (p44/42 MAPK;
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Figure 1. Hindbrain GLP-1R Activation
Suppresses Food Intake by Increasing
Protein Kinase-A Activity
(A) Increased PKA activity (nmol/g/min) in tissue of
the caudal DVC following fourth i.c.v. Ex-4 (0.3 mg)
administration. *p < 0.05 from aCSF. Cumulative
chow intake (B) and 24 hr BW change (C) following
fourth i.c.v. delivery of the PKA inhibitor RpcAMP
(20 mg) or Ex-4 (0.2 mg) alone or in combination,
counterbalanced with vehicle/vehicle (aCSF/
aCSF). Data are mean ± SEM. *p < 0.05 from
vehicle/vehicle. yp < 0.05 from vehicle/Ex-4.
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Intracellular Hindbrain GLP-1 Signalingalso known as extracellular signal-regulated kinase [ERK]-1/2)
(Dugan et al., 1999; Vossler et al., 1997), presumably through
a PKA-dependent pathway (Ma et al., 2007). GLP-1 stimulates
p44/42 MAPK phosphorylation in pancreatic b cells through
a mitogen-activated protein kinase kinase (MEK)-dependent
but Raf/Ras-independent pathway that requires PKA activation,
an influx of extracellular Ca2+, and calmodulin-dependent
protein kinase II (CaMKII) activation (Gomez et al., 2002).
Previous reports highlight a role for p44/42 MAPK signaling
within the NTS in food intake control (Sutton et al., 2004,
2005). Yet, direct in vivo and in vitro evaluation of the MAPK
pathway mediating the intake suppressive effects of hindbrain
GLP-1R activation remains unaddressed.
PKA activation is also known to inhibit calmodulin-dependent
protein kinase kinase (CaMKK) (Hurley et al., 2006). CaMKK and
LKB1 have been identified as the principal upstream kinases
which phosphorylate the fuel-sensing enzyme AMP-activated
protein kinase (AMPK) a catalytic subunit at Thr172 (for review,
see Xue and Kahn, 2006). Thus, a PKA-induced inhibition
of CaMKK activity would lead to decreased AMPK activation
(Hurley et al., 2006). AMPK has been implicated in CNS control
of energy balance (Minokoshi et al., 2004; Seo et al., 2008;
Xue and Kahn, 2006), and its activity is altered by food depriva-
tion (da Silva Xavier et al., 2003; Minokoshi et al., 2004; Xue
and Kahn, 2006) and by the effects of leptin, insulin-induced
hypoglycemia, or 2-DG cytoglucopenia (Han et al., 2005; Hayes
et al., 2009b, 2010b; Kim and Lee, 2005; Kim et al., 2004b;
Minokoshi et al., 2004). In addition, increased hypothalamic
AMPK mRNA following food deprivation was attenuated by
GLP-1R activation (Seo et al., 2008). Recently, the role of
AMPK activity in NTS control of energy balance has also been
evaluated (Hayes et al., 2008a). Similar to previous reports
evaluating AMPK activity in various hypothalamic nuclei (Mino-
koshi et al., 2004; Xue and Kahn, 2006), it was found that foodCell Metabolism 13, 320–3deprivation increases AMPK activity in
NTS lysates and that AMPK activity within
the NTS is physiologically relevant to the
normal control of food intake (Hayes
et al., 2009b, 2010b). Together, these
data support the hypothesis that reduced
AMPK activity in the hindbrain may
mediate the suppression of intake that
follows GLP-1R activation.
Using a combination of in vivo and
in vitro techniques, we evaluate the
cellular signaling pathways that mediatethe food intake and BW-suppressive effects of hindbrain GLP-
1R activation by the GLP-1R-selective agonist, Exendin-4
(Ex-4). We hypothesize that activation of NTS-GLP-1R-express-
ing neurons suppresses food intake through coordinated
PKA-mediated suppression of AMPK activity and PKA-mediated
activation of p44/42 MAPK.
RESULTS
Hindbrain GLP-1R Activation Reduces Food Intake
by Increasing PKA Activity
Hindbrain administration of the GLP-1R agonist Ex-4 (0.3 mg;
fourth i.c.v.) significantly increased PKA activity in the dorsal
vagal complex (DVC; which includes NTS, dorsal motor nucleus
of the vagus [DMV], and area postrema [AP]) at 10 and 20 min
postinjection compared to aCSF (Figure 1A). By 30 min, the
Ex-4-driven elevation in NTS PKA activity had returned to base-
line levels.
To test the hypothesis that the intake-suppressive effects of
hindbrain GLP-1R activation require PKA activity, intake of stan-
dard rodent chow was examined following counterbalanced
fourth i.c.v. administration of Ex-4 (0.2mg) aloneor in combination
with the widely used PKA inhibitor, RpcAMP (20 mg). Figure 1B
shows that cumulative food intake was significantly suppressed
at 3, 6, and 24 hr following Ex-4 administration. This intake
suppression was dependent on an increase in hindbrain PKA
activity, as fourth i.c.v. pretreatment with the PKA inhibitor
RpcAMP reversed the intake suppressive effects of fourth i.c.v.
Ex-4 at 3 and 6 hr and attenuated the intake suppression at
24 hr. fourth i.c.v. Ex-4 administration also significantly sup-
pressed BW 24 hr after administration compared to vehicle/
vehicle (aCSF/aCSF) treatment (Figure 1C). Pretreatment with
RpcAMP significantly attenuated the suppression of BW by
fourth i.c.v. Ex-4, whereas RpcAMP alone did not affect BW.30, March 2, 2011 ª2011 Elsevier Inc. 321
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Figure 2. Hindbrain GLP-1R Activation Suppresses Food Intake by Increasing Phosphorylation of Mitogen-Activated Protein Kinase
(A) Increased phosphorylation of p44/42-MAPK in caudal DVC tissue lysates following fourth i.c.v. Ex-4 (0.3 mg) administration. Representative immunoblots for
phosphorylated and total p44/42-MAPKare shown. *p < 0.05 from aCSF. Cumulative chow intake (B) and 24 hr BWchange (C) following fourth i.c.v. delivery of the
MEK inhibitor U0126 (2 mg) or Ex-4 (0.2 mg) alone or in combination, counterbalanced with vehicle/vehicle (DMSO/aCSF). Data are mean ± SEM. *p < 0.05 from
vehicle/vehicle. yp < 0.05 from vehicle/Ex-4.
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Intracellular Hindbrain GLP-1 SignalingHindbrain GLP-1R Activation Suppresses Food Intake
by Increasing Phosphorylation of MAPK
Immunoblot analysis revealed that fourth i.c.v. Ex-4 (0.3 mg)
administration increased p44/42 MAPK phosphorylation in
DVC tissue compared to vehicle (aCSF) (Figure 2A; data pre-
sented as phosphorylated/total MAPK). Specifically, hindbrain
Ex-4 significantly increased phosphorylation of p44 MAPK at
10 and 30 min postadministration with no change in total p44
levels. Likewise, fourth i.c.v. Ex-4 increased phosphorylation of
p42 at 10, 20, and 30 min postadministration. For both p44
and p42 MAPK, the greatest increase in phosphorylation was
observed at 30 min following hindbrain GLP-1R activation.
Food intake was significantly suppressed following fourth
i.c.v. Ex-4 (0.2 mg) administration in a separate group of rats at
3, 6, and 24 hr postinjection compared to vehicle/vehicle
(DMSO/aCSF) administration (Figure 2B). Blockade of MAPK
signaling by fourth i.c.v. administration of the MEK inhibitor,
U0126, had no effect on food intake when administered alone.
Pretreatment with U0126, however, significantly reversed the
inhibition of intake by Ex-4 at 3 and 6 hr. BW was also signifi-
cantly suppressed 24 hr after fourth i.c.v. Ex-4 administration
compared to vehicle/vehicle treatment (Figure 2C). Fourth i.c.v.
administration of U0126, while having no effect on 24 hr BW
when administered alone, significantly attenuated the suppres-
sion of BW by fourth i.c.v. Ex-4.
Hindbrain GLP-1R Activation Reduces Food Intake via
Inhibition of AMPK Signaling
Immunoblot analysis revealed that hindbrain GLP-1R activation
by fourth i.c.v. Ex-4 (0.3 mg) significantly reduced phosphoryla-322 Cell Metabolism 13, 320–330, March 2, 2011 ª2011 Elsevier Inc.tion of AMPKa2 in DVC tissue at 20 and 30 min postadministra-
tion, with no change in total AMPKa levels (Figure 3A; data pre-
sented as pAMPKa2/total AMPKa). Inhibition of NTS AMPK
activity following hindbrain GLP-1R activation was greatest at
30 min.
In a separate cohort of rats, the AMPK activity promoter,
AICAR, was used to investigate whether inhibition of AMPK
activity mediates the suppression of food intake by Ex-4
(measured by automated feedometers that record food intake
to the nearest ± 0.1 g/m/24 hr every 1 min). Hindbrain GLP-1R
activation by fourth i.c.v. Ex-4 suppressed food intake in the
dark cycle by reducing meal number and increasing intermeal
interval, not by altering meal size (Figure 4A). A maximum 44%
intake suppression by Ex-4 occurred 12 hr postinjection (at the
start of light cycle; Figure 3B). Fourth i.c.v. AICAR attenuated
Ex-4’s intake-suppressive effect by approximately 50% (Fig-
ure 3B) and attenuated Ex-4’s suppression of meal number
and increase in intermeal interval (Figure 4A). The change in
24 hr BW was significantly suppressed by fourth i.c.v. Ex-4 (Fig-
ure 3C) compared to BW change following vehicle. AICAR alone
did not alter 24 hr BW. Pretreatment with AICAR produced
a nonsignificant trend of an attenuation in the suppression of
BW by fourth i.c.v. Ex-4 (p = 0.065 for BW change comparison
between vehicle/Ex-4 and AICAR/Ex-4 treatments), whereas
AICAR alone did not alter 24 hr BW.
Hindbrain GLP-1R activation (fourth i.c.v. Ex-4) reduces food
intake that results from the suppression in meal number, with
no alteration in meal size (see Figures S1A and S1B available
online). In a separate group of rats, IP Ex-4 (3.0 mg/kg) adminis-
tration suppressed food intake by approximately 47% at 5 hr
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Figure 3. Suppression of Intake by Hindbrain GLP-1R Activation Is Meditated by Reduced AMPK Signaling
(A) Decreased phosphorylation of AMPKa2 in caudal DVC tissue lysates following fourth i.c.v. Ex-4 (0.3 mg) administration. Representative immunoblots for
pAMPKa2 and total AMPKa are shown. *p < 0.05 from aCSF. Cumulative chow intake (B) and 24 hr BW change (C) following fourth i.c.v. delivery of the
AMPK activity promoter AICAR (300 mg) or Ex-4 (0.1 mg) alone or in combination, counterbalanced with vehicle/vehicle (aCSF/aCSF). Chow intake recorded
via automated feedometers that continuously record food intake to the nearest ± 0.1 g/m/24 hr. Data are mean ± SEM. *p < 0.05 from vehicle/vehicle.
#p = 0.065 from vehicle/Ex-4.
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Intracellular Hindbrain GLP-1 Signalingpost-drug delivery through a reduction inmeal size, with no alter-
ation in meal number (Figure S1B). Thus, the time point chosen
for meal pattern assessment for fourth i.c.v. and IP Ex-4 admin-
istration in Figures S1A and S1B is based on comparable
maximum percent suppression of chow intake (45%
suppression).
The Hindbrain GLP-1R-Mediated Increase in MAPK and
Reduction in AMPK Signaling Are PKA Dependent
Immunoblot analysis showed that the increase in MAPK phos-
phorylation and decrease in pAMPKa2 by fourth i.c.v. Ex-4
administration is dependent, in part, on PKA activation. Inhibition
of hindbrain PKA activity by fourth i.c.v. pretreatment with
RpcAMP (20 mg) significantly attenuated the Ex-4 (0.3 mg; fourth
i.c.v.)-induced decrease in NTSpAMPKa2 levels (Figure 4A; data
presented as pAMPKa2/total AMPKa). Likewise, RpcAMP
significantly attenuated the Ex-4-induced increase in phosphor-
ylated p42-MAPK levels, but not p44-MAPK levels in DVC tissue
(Figure 4B; data presented as phosphorylated/total MAPK).
Medial NTS GLP-1Rs Mediate the Intake-Suppressive
Effects of Hindbrain Ex-4
Ex-4was administered intraparenchymally to themNTS, AP, and
DMV to determine the hindbrain-specific GLP-1R-expressing
nucleus within the DVC that mediates the intake suppressive
effects of fourth i.c.v. Ex-4. First, a subthreshold dose for intake
suppression of Ex-4 was determined for fourth i.c.v. delivery, asCefourth i.c.v. Ex-4 (0.05 mg/1 ml) significantly suppressed chow
intake at 6 and 24 hr postadministration, whereas fourth i.c.v.
Ex-4 (0.025 mg/1 ml) was without effect (Figure 5A). Unilateral
intraparenchymal mNTS administration of Ex-4 at 0.025 mg/100
nl significantly suppressed chow intake at 3, 6, and 24 hr postad-
ministration; 0.05 mg/100 nl was also effective (Figure 5B).
Conversely, unilateral DMV administration of Ex-4 at 0.05 mg/
100 nl, a dose effective following either fourth i.c.v. or mNTS
delivery, was without effect on food intake (Figure 5C). A similar
absence of an intake-suppressive effect was observed following
intraparenchymal Ex-4 administration to the AP at 0.025 mg/
100 nl and 0.05 mg/100 nl (Figure 5D).
In addition to postmortem histological verification of intrapar-
enchymal cannula placement for the mNTS, AP, and DMV, func-
tional tests were performed to further confirm placement of
mNTS and AP injection sites. The AP has been shown tomediate
the intake suppressive effects of the pancreatic hormone amylin
and its agonist, salmon calcitonin (sCT) (Mollet et al., 2004; Potes
and Lutz, 2010). AP administration of sCT at 0.4 mg/100 nl, a dose
previously established to be just at threshold for intake suppres-
sion when administered to the fourth ventricle (Mollet et al.,
2004), produced a significant suppression of food intake at all
time points measured (Figure 5E), thus providing functional
confirmation of our AP site of delivery. To confirmmNTS injection
sites, the cytoglucopenia-induced sympathoadrenal-mediated
glycemic effect resulting from intraparenchymal injection of
24 mg of 5-thio-D-glucose in 100 nl of aCSF (Hayes et al.,ll Metabolism 13, 320–330, March 2, 2011 ª2011 Elsevier Inc. 323
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p44-MAPK by Ex-4. Data are mean ± SEM. *p < 0.05 from aCSF/aCSF. yp < 0.05 from aCSF/Ex-4.
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Intracellular Hindbrain GLP-1 Signaling2009b, 2010b) was performed. A hyperglycemic response
(R100% of basal glycemia) verified cannula placement.
GLP-1R-Expressing GT1-7 Neurons
Show Exendin-4-Mediated Increases in cAMP/PKA
andMAPKSignaling,andSuppressionofAMPKSignaling
Total cAMP levels were evaluated in GLP-1R-expressing GT1-7
neuronal cells (Beak et al., 1998; Yang et al., 2005) following
15 min of Ex-4 treatment (0.0, 0.01, 0.1, 1.0, 10 nmol). Figure 6A
shows that GLP-1R activation by Ex-4 dose dependently
increased total cAMP levels in GT1-7 neurons, with 0.1, 1.0,
and 10.0 nmol of Ex-4 significantly increasing total cAMP levels
compared to vehicle (aCSF).
Immunoblot analysis showed a significant dose-dependent
decrease in pAMPKa2 levels in GT1-7 neurons following
15 min Ex-4 treatment (0.0, 1.0, 10, and 100 nmol; Figure 6B;
data presented as pAMPKa2/total AMPKa). In addition, Ex-4
treatment dose-dependently increased phosphorylated p44/42
MAPK levels in GT1-7 neurons (Figure 6C; data presented as
phosphorylated/total MAPK). Ex-4 treatment did not, however,
significantly alter either total AMPKa or total p44/42-MAPK
levels.
DISCUSSION
Pharmacological agents targeting the peripheral GLP-1 system
are used to treat T2DM and may also prove to be efficacious in324 Cell Metabolism 13, 320–330, March 2, 2011 ª2011 Elsevier Inc.obesity treatment (Hayes et al., 2010a; Holst, 2007; Larsen
et al., 2003; Lovshin and Drucker, 2009). A variety of evidence
indicates that activation of central GLP-1Rs engages a behav-
ioral and physiological profile of responses that is similar to
that observed following activation of peripheral GLP-1Rs and
therefore may provide another pharmacological strategy to
regulate blood glucose levels and reduce excessive adiposity
by decreasing energy intake. Of the various brain regions con-
taining GLP-1R-expressing neurons, previous reports establish
those in the NTS as a physiologically relevant population of
central GLP-1Rs in food intake control (Hayes et al., 2008b,
2009a; Kinzig et al., 2002). The intracellular signaling pathways
mediating food intake suppression following NTS GLP-1R
activation have not been previously established. Here we show
that the suppression of food intake and BW following activation
of hindbrain GLP-1Rs involves a coordinated PKA-mediated
suppression in AMPK activity and activation of p44/42-MAPK
signaling in the NTS.
Our working model (Figure 7, modified from Hayes et al.,
2010a) derives from the current data, as well as previous
reports examining the intracellular signaling cascades following
GLP-1R activation in pancreatic b cells (Gomez et al., 2002;
Perfetti and Merkel, 2000), from known signaling pathways
downstream of cAMP/PKA activation in neuronal cells (Dugan
et al., 1999; Vossler et al., 1997), and from recent reports
showing that increased AMPK mRNA in the hypothalamus
following food deprivation is attenuated by GLP-1R activity
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Figure 5. Medial NTS GLP-1R Activation
Suppresses Food Intake
(A–D) Cumulative chow intake following (A) hind-
brain (fourth i.c.v.) delivery of Ex-4 (0.025 mg and
0.05 mg in 1 ml), (B) unilateral intraparenchymal
mNTS delivery of Ex-4 (0.025 mg and 0.05 mg in
100 nl), (C) unilateral intraparenchymal DMV
delivery of Ex-4 (0.05 mg in 100 nl), (D) intraparen-
chymal AP delivery of Ex-4 (0.025 mg and 0.05 mg
in 100 nl), counterbalanced with aCSF.
(E) Functional verification of AP injections
measured by cumulative 4 hr chow intake
following AP administration of the amylin (calci-
tonin) receptor agonist, salmon calcitonin (sCT)
(0.4 mg in 100 nl) counterbalanced with aCSF.
Data are mean ± SEM. * = p < 0.05 from aCSF.
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following NTS GLP-1R activation that involve increased PKA
and MAPK signaling and decreased AMPK signaling engage
additional intracellular signaling cascades, as well as neuronal
projections to other brain regions relevant to energy balance
control. In addition to the intake-inhibitory responses produced
by fourth i.c.v. Ex-4 administration, hindbrain GLP-1R signaling
also triggers energy expenditure responses including hypo-
thermia and tachycardia (Hayes et al., 2008b). Interestingly,
inhibition of hindbrain AMPK activity also increases heart rate
and locomotor activity in rats. Therefore, it is plausible that
energy expenditure responses produced by hindbrain GLP-1R
activation would involve AMPK signaling (Hayes et al., 2009b).
However, it remains to be determined whether energetic
responses mediated by hindbrain GLP-1R activation involve
the same PKA, MAPK, and AMPK intracellular signaling
cascades as described here for food intake.
Previous reports show that the GLP-1R-expressing NTS
neurons are the likely mediators of the intake-suppressive
effects of hindbrain ventricular Ex-4 administration (Hayes
et al., 2008b, 2009a). Direct pharmacological blockade of
mNTS GLP-1Rs increases food intake (Hayes et al., 2009a), indi-
cating that endogenous NTS GLP-1R activation contributes to
the physiological control of food intake. Vagal afferent signals
arising from distension of the stomach appear to engage NTS
GLP-1R signaling (Hayes et al., 2009a) following activation of
the proglucagon-expressing neurons of the NTS (Vrang et al.,
2003), which increases endogenous CNS GLP-1 ligand
availability. Data presented in this report show that the food
intake-suppressive effects of DVC parenchymal application of
a GLP-1R ligand aremediated bymNTS neurons, as a significant
suppression of intake was observed following Ex-4 delivery to
the mNTS at a fourth i.c.v. subthreshold dose (0.025 mg), effects
not observed following administration of Ex-4 at the same dose
or even at a ventricular-effective dose (0.05 mg) to other hindbrainCell Metabolism 13, 320–3GLP-1R-expressing nuclei (i.e., AP or
DMV). Moreover, using a combination of
in vivo and in vitro techniques with the
GLP-1R ligand Ex-4, we demonstrate
that the intake-suppressive effects of
NTS-GLP-1R activation occur through
a coordinated PKA-mediated suppres-sion of AMPK activity and activation of p44/42 MAPK signaling.
These effects may promote Ca+-dependent depolarization of the
GLP-1R-expressing neurons and longer-term cAMP response
element-binding protein (CREB)-mediated transcriptional
effects. The present findings further suggest that the intake-
suppressive effects of gastric distension may also be mediated
in part by an increase in PKA, MAPK, and possibly CREB
signaling, as well as inhibition of AMPK signaling within NTS
neurons. It may also be the case that NTSmediation of the intake
inhibitory responses of other anorectic signals (e.g., cholecysto-
kinin, melanocortin, leptin) that engage these intracellular
signaling pathways (Hayes et al., 2009b, 2010b; Sutton et al.,
2004, 2005) could potentially reduce food intake in a synergistic
fashion with either CNS GLP-1R ligands and/or gastric disten-
sion. Given that PKA inhibition did not completely reverse the
24 hr intake suppression by fourth i.c.v. Ex-4, it is also reason-
able to assume that other non-PKA-dependent signaling path-
ways may mediate the suppression of intake by hindbrain
GLP-1R activation.
While caudal brainstem processing (in the absence of fore-
brain communication) is sufficient to mediate the food intake-
suppressive effects following fourth i.c.v. Ex-4 administration
(Hayes et al., 2008b), the NTS is not the only CNS GLP1-R-ex-
pressing nucleus relevant to energy balance control (e.g., PVH;
central nucleus of the amygdala, CeA; dorsal medial hypothal-
amus, DMH). Indeed, parenchymal application of GLP-1(7-36)
in the PVH suppresses food intake in rats (McMahon and Well-
man, 1997, 1998). Whether the intracellular signaling cascades
for PVH or other GLP-1R-expressing neurons are identical to
those reported here for the DVC GLP-1R remains to be deter-
mined. It may be possible that in GLP-1R-expressing nuclei
outside the NTS, different intracellular signaling pathways may
mediate different behavioral/physiological responses produced
by GLP-1R activation. Such a case has been made previously
for the angiotensin receptor (Daniels et al., 2005). Nonetheless,30, March 2, 2011 ª2011 Elsevier Inc. 325
AC
B
Figure 6. GLP-1R-Expressing GT1-7 Neurons Show Exendin-4-Mediated Increases in cAMP/PKA and MAPK Signaling, and Suppression of
AMPK Signaling
(A) Total cAMP levels in 3 hr serum-starved GLP-1R-expressing GT1-7 neuronal cells following 15 min treatment with Ex-4 (0.0, 0.01, 0.1, 1.0, 10 nmol). *p < 0.05
from vehicle (0.0 nmol Ex-4). (B) Ex-4 treatment (0.0, 1.0, 10, and 100 nmol; 15 min) dose-dependently decreased pAMPKa2 and (C) increased phosphorylated
p44/42 MAPK in the GLP-1R-expressing GT1-7 neurons. Data are mean ± SEM. *p < 0.05 from vehicle (0.0 nmol Ex-4).
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1R-expressing neurons are similar throughout the brain, as the
ex vivo signaling responses reported here for the DVC tissue
lysates were also found in vitro in immortalized hypothalamic
GLP-1R-expressing GT1-7 cells. It is virtually impossible to
rule out the possibility that intracellular signaling inhibitors/acti-
vators (e.g., U0126/AICAR) attenuate the behavioral intake
suppression of fourth i.c.v. Ex-4 by acting on both GLP-1R-
and non-GLP-1R-expressing neurons.
Hindbrain Ex-4 administration rapidly increases NTS PKA
activity, with a peak in activity occurring 10 min postadminis-
tration and a return to baseline (vehicle) levels seen at 30 min
postadministration. Yet behavioral analyses show that the
suppression of food intake by fourth i.c.v. Ex-4 is observed
by the third hour postadministration, an effect dependent
upon an increase in PKA and MAPK activity, as well as
a decrease in AMPK activity. This distinction in the time course
effects for the intracellular signaling cascades from tissue
lysates and those for the food intake response have been
reported previously for other anorectic ligands and intracellular
signals acting within the brain (Morton et al., 2009; Niswender
et al., 2001; Sutton et al., 2005). These observations can be in-
terpreted to suggest that although PKA, MAPK, and AMPK
signaling are required to mediate the suppression of intake
by NTS GLP-1R activation, other downstream signaling
cascades and recruitment of neurons of other CNS nuclei are
also required to mediate the intake-suppressive action of hind-326 Cell Metabolism 13, 320–330, March 2, 2011 ª2011 Elsevier Inc.brain Ex-4. These additional signaling cascades and neuronal
projections arising from NTS GLP-1R-expressing neurons
remain to be identified.
That suppression in meal number accounts for the reduced
food intake resulting from hindbrain Ex-4 supports the notion
that the central GLP-1 system is different, but complementary
to, the peripheral GLP-1 system. This conclusion is based in
part on data presented here, as well as on previous observa-
tions (Ruttimann et al., 2009; Scott and Moran, 2007) that
show that the short-term intake-inhibitory effects of peripheral
GLP-1R activation result from a reduction in meal size, with
minimal effect on meal number. It may be possible that periph-
eral administration of Ex-4 or other DPP-IV-resistant GLP-1R
ligands with longer half-lives than GLP-1(7-36) (e.g., liraglutide)
may reduce food intake across a longer period of time by simul-
taneous activation of both peripheral and central GLP-1
systems.
In conclusion, current findings demonstrate that the food
intake- and BW-suppressive effects of hindbrain GLP-1R activa-
tion are dependent upon an increase in PKA activity and subse-
quent simultaneous phosphorylation of p44/42-MAPK and inhi-
bition of AMPK activity in NTS neurons. Ex-4 activation of the
same signaling cascades in GT1-7 neuronal cells and in NTS
lysates supports the view that these pathways occur in GLP-
1R-expressing neurons. Together with our previous reports
(Hayes et al., 2008b, 2009a), current data demonstrate that
NTS GLP-1R-expressing neurons play a physiological role in
Figure 7. Intracellular Signaling Pathways in NTS GLP-1R-Express-
ing Neurons Mediating Food Intake Suppression by Hindbrain GLP-
1R Ligands
Gastric vagal afferent signaling increases endogenous NTS-derived GLP-1,
which activates endemic NTS GLP-1R-expressing neurons (Hayes et al.,
2009a) to engage cAMP-dependent increase in PKA activity. Increased PKA
activity concomitantly increases phosphorylation of p44/42-MAPK and
decreases phosphorylation of AMPK. The combined increase in PKA and
p44/42-MAPK activity together with decreased AMPK activity is hypothesized
to increase CREB-mediated nuclear transcription and protein synthesis.
mTOR, mammalian target of rapamycin; CAMKK, calmodulin-dependent
protein kinase kinase; CAMKII, calcium/calmodulin-dependent protein kinase
II; VGCC, voltage gated calcium channel; MEK, mitogen-activated protein
kinase kinase.
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provide clues to understanding how NTS neurons mediate
anorectic actions of other stimuli involved in meal-to-meal food
intake control. Future pharmacotherapies targeting not only
NTS GLP-1R but the CNS GLP-1 system as a whole may prove
to be efficacious in ameliorating chronic hyperphagia associated
with obesity.
EXPERIMENTAL PROCEDURES
Subjects and Materials
Individually housed, adult male Sprague Dawley rats (300–350 g; Charles
River), maintained at 23C with 12 hr/12 hr light/dark cycle (10:00 hr lights
off), had ad libitum access to chow (Purina Rodent Chow 5001) and water
except as noted. All procedures conformed to the institutional standards of
the animal care and use committee (University of Pennsylvania).
The following compounds were utilized to examine hindbrain GLP-1R-medi-
ated control of food intake: the DPP-IV-resistant GLP-1R agonist, Ex-4
(American Peptide Co.) (Hayes et al., 2008b); adenosine-30,50-cyclic mono-
phosphorothioate Rp-isomer (RpcAMP; Sigma), a widely used inhibitor of
cAMP-dependent activation of PKA (Dostmann et al., 1990; Kelly et al.,
2007; Sheriff et al., 2003); the AMP-mimicking promoter of AMPK activity,
5-aminoimidazole-4-carboxamide-1-b-D-riboside (AICAR; Fisher Scientific)
(Hayes et al., 2009b; Kim et al., 2004a); and the selective MEK inhibitor
U0126 (Tocris Bioscience), which blocks p44/42 MAPK phosphorylation
(Daniels et al., 2003; Sutton et al., 2005; Sutton et al., 2004). All drugs were
administered in unrestrained animals in a counterbalanced fashion, with all
drug combinations for a given experiment being administered on any given
experimental day. For behavioral testing, each experimental trial was sepa-
rated by a minimum of 48 hr.CeFourth Intracerebroventricular/mNTS/AP/DMV Cannulation
Surgery
Under ketamine (90 mg/kg), xylazine (2.7 mg/kg), and acepromazine
(0.64 mg/kg) anesthesia and analgesia (Metacam 2 mg/kg), guide cannulas
(Plastics One; 26-gauge) were implanted at the following coordinates: fourth
i.c.v., 2.0 mm above fourth ventricle, 2.5 mm anterior to occipital suture,
4.5 mm ventral to dura, and on midline; bilateral caudal mNTS, 2.0 mm above
mNTS, 1.0 mm posterior to occipital crest, ±0.7 mm lateral to midline, 6.7 mm
ventral from skull surface; AP, 2.0 mm above AP, 1.0 mm posterior to occipital
crest, on midline, 6.4 mm ventral from skull surface; bilateral DMV, 2.0 mm
above DMV, 1.0 mm posterior to occipital crest, ±0.7 mm lateral to midline,
6.9 mm ventral from skull surface (Hayes and Covasa, 2006; Hayes et al.,
2009b, 2010b; Paxinos and Watson, 1998). Intended anatomical positions of
fourth i.c.v./mNTS injection sites were evaluated 1 week postsurgery as
described (Hayes et al., 2009b, 2010b). Behavioral testing began 12 days
following surgery. All DVC intraparenchymal injection sites were anatomically
confirmed via postmortem verification of the position of 100 nl pontamine sky
blue injections. Only animals passing both functional and histological verifica-
tions were included in final statistical analyses.Signaling Analysis
Ex Vivo Tissue Collection
Tissue of the caudal DVC of ad libitum chow-fed rats, were prepared as
described (Hayes et al., 2009b; Minokoshi et al., 2004). Briefly, at dark cycle
onset, rats received a fourth i.c.v. injection of Ex-4 (0.3 mg) or aCSF vehicle
and were sacrificed 10, 20, or 30 min later by decapitation. Brains were rapidly
removed; tissue lysates were collected from the DVC (Hayes et al., 2009b) and
samples flash frozen in isopentane and stored at 80C. To collect caudal
DVC tissue, brains were positioned with dorsal surface up, and the cerebellum
was removed. The calamus scriptorius (most caudal portion of the fourth
ventricle) provides a landmark for isolating caudal dorsomedial DVC tissue.
Coronal sections were made 1mm anterior and 2mm posterior to the calamus
scriptorius. Bilateral sagittal cuts were made 2 mm lateral to the midline.
A horizontal cut was then made 0.5 mm ventral to the central canal (Hayes
et al., 2009b; Huo et al., 2006).
To determine whether the decrease in pAMPKa2 levels and increase in
phosphorylated p44/42-MAPK levels by hindbrain GLP-1R activation are
dependent on PKA activation, a separate group of ad libitum-fed rats (n =
3/treatment) received a fourth i.c.v. injection of aCSF vehicle (1 ml) counterbal-
anced with RpcAMP (20 mg) at dark cycle onset. Twenty minutes later, rats
received a fourth i.c.v. injection of Ex-4 (0.3 mg) counterbalanced with aCSF.
Rats were sacrificed 20 min following the second set of injections, and brains
were rapidly removed and tissue of the caudal DVC was collected.
In Vitro GLP-1R-Expressing Immortalized GT1-7 Neuronal Cells
GT1-7 hypothalamic neuroblastoma cells (generous gift from Dr. Sangwon
Kim, University of Pennsylvania) that highly express the GLP-1R (Beak et al.,
1998; Yang et al., 2005) were maintained at 37C in 5% CO2 and were
cultured in 13 DMEM with 4.5 mg/ml glucose (GIBCO/Invitrogen), 10% (v/v)
fetal bovine serum (Thermo Fisher Scientific Inc.), and 2% penicillin
(10,000 I.U./ml)-streptomycin (10,000 ug/ml) solution (Mediatech, Inc.). Three
hour serum-starved GT1-7 neurons were treated with Ex-4 (0.0, 1.0, 10,
100 nmol) for 15 min. At the end of the incubation, mediumwas removed, cells
were washed in ice-cold 0.1M PBS, and lysates were prepared by scraping
cells into 500 ml of 1% NP-40 lysis buffer containing fresh protease and phos-
phatase inhibitors and repetitively passing the lysates through a 26-gauge
needle followed by 10min centrifugation (12,000 rpm) at 4C to pellet out insol-
uble material.
Biochemistry
Caudal DVC tissue and GT1-7 neuronal cell lysates were subjected to SDS-
PAGE and transferred to PVDF membranes for immunoblot analysis (Hayes
et al., 2009b, 2010b). pAMPKa-Thr 172 rabbit monoclonal antibody
(pAMPKa2; Cell Signaling; catalog number 2535S) was used to evaluate
AMPK activity and was normalized to total AMPKa (reactive against a1 and
a2 subunits; Cell Signaling). Phospho-p44/42 MAPK polyclonal antibody
(Thr202/Tyr204; Cell Signaling; catalog number 9101S) was used to assess
MAPK signaling and was normalized to total p44/42 MAPK (Cell Signaling;
catalog number 9102). Blots were quantified using NIH Image software.ll Metabolism 13, 320–330, March 2, 2011 ª2011 Elsevier Inc. 327
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(Stressgen Assay Designs; catalog number EKS-390A).
Determination of cAMP Levels
Measurement of total cAMP was conducted using the Biotrak cAMP enzyme
immunoassay system (GE Healthcare/Amersham Biosciences, USA).
Three hour serum-starved GT1-7 neurons, cultured in a 96-well culture plate
(6 3 104 cells/well), were treated with Ex-4 (0.0, 0.01, 0.1, 1.0, 10 nmol) for
15 min. cAMP levels were calculated using a standard curve of fmol of
cAMP/104 GT1-7 neurons.
Feeding Behavior
Hindbrain PKA Activity
One hour prior to the dark cycle, ad libitum-fed rats (n = 7) received a fourth
i.c.v. injection of aCSF vehicle (1 ml) counterbalanced with RpcAMP (20 mg)
(dose selection, Kelly et al., 2007) 45 min prior to a fourth i.c.v. injection of
Ex-4 (0.2 mg) (dose subthreshold for intake suppression by IP administration
from pilot work [data not shown] and [Mack et al., 2006]) counterbalanced
with aCSF. Five minutes following the second drug administration, immedi-
ately prior to dark onset, rats were presented with preweighed maintenance
rat chow, and intakes were recorded to the nearest 0.1 g at 1, 3, 6, and
24 hr post-food presentation.
Hindbrain MAPK Signaling
One hour prior to the dark cycle, a separate group of ad libitum fed rats (n = 8)
received a fourth i.c.v. injection of vehicle (dimethylsulfoxide [DMSO]; 1 ml]
counterbalanced with U0126 (2 mg dissolved in DMSO) 45 min prior to a fourth
i.c.v. injection of Ex-4 (0.2 mg) counterbalanced with aCSF (U0126 dose and
injection time course chosen from pilot dose response study [data not shown;
and Sutton et al., 2005]). Cumulative chow intake was recorded at 1, 3, 6, and
24 hr.
Hindbrain AMPK Signaling
In a separate group of ad libitum-fed rats (n = 6), the role of hindbrain AMPK
signaling in mediating the intake suppressive effects of fourth i.c.v. Ex-4 was
evaluated using automated feedometers designed in our lab. Briefly, feedom-
eters consisted of a standard Nalgene rodent bin (183 93 8 inches for length,
width, and depth, respectively) with permanent, externally mounted food
hoppers. Rats had ad libitum access to pelleted chow through a 3.5 3 2.5
inch square hole in the chamber. The externally mounted food hoppers were
housed in and rested on a custom-built reinforced acrylic cup (to catch
spillage) attached to a leveled load cell (Omega Engineering, Inc; LCAE-1KG).
The weight of the chow + spillage was recorded to the nearest 0.1 g/min and
relayed to computer via processmeter (Omega Engineering, Inc; DP25B). Data
were processed by computer software (National Instruments; LabVIEW; Penn
8 Channel Feed Monitor 1.0.0) to determine food ingestion each 1 min, and
a total food intake curve was cumulated for 24 hr. Two hours prior to the
dark cycle, automated food intake readings began. One hour later, rats
received fourth i.c.v. injection of aCSF (3 ml) counterbalanced with AICAR
(300 mg dissolved in aCSF), followed 45min later by a second fourth i.c.v. injec-
tion (1 ml) of Ex-4 (0.1 mg) counterbalanced with aCSF (Hayes et al., 2009b). A
meal was defined as a bout of eating at least 0.25 mg of food followed by
10 min of no eating. These meal parameters accounted for >95% of the
24 hr cumulative food intake.
Meal Pattern Analysis of the Intake-Suppressive Effects Following
Peripheral GLP-1R Activation
In a separate group of ad libitum chow-fed rats (n = 7), the meal pattern effects
mediating the intake suppression following peripheral (IP) Ex-4 (3.0 mg/kg)
administration were evaluated to allow for comparisons with the aforemen-
tioned meal pattern effects following fourth i.c.v. Ex-4. As detailed above,
data were processed to determine the continuous cumulative intake for
24 hr, as well as analyzed for the meal pattern effects of the drugs injected.
Two hours prior to the dark cycle, automated food intake readings began.
Fifteenminutes prior to the onset of the dark cycle, rats received an IP injection
of Ex-4 counterbalanced with 0.9% saline vehicle (1 ml/kg). Dose and time
course selection of drug delivery was chosen from Hayes et al. (2009b) and
pilot studies to yield a 40%–50% maximum suppression in food intake.
Intraparenchymal mNTS/DMV/AP Ex-4 Administration
In separate groups of rats fed chow ad libitum, individual nuclei within the DVC
were targeted to determine which site(s) contributed to the mediation of the
intake-suppressive effects of hindbrain (fourth i.c.v.) Ex-4 delivery. First, to328 Cell Metabolism 13, 320–330, March 2, 2011 ª2011 Elsevier Inc.establish a fourth i.c.v. dose of Ex-4 that is without effect on intake, we admin-
istered Ex-4 fourth i.c.v. at 0.025 mg and 0.05 mg counterbalanced with 1 ml
aCSF, 5 min prior to dark onset. Rat (n = 7) intake of chow was recorded at
1, 3, 6, and 24 hr.
Having established that the 0.025 mg dose of Ex-4 is subthreshold for intake
suppression when administered to the fourth ventricle, the relevant GLP-1R-
expressing nucleus within the DVC mediating the intake suppressive effects
of fourth i.c.v. Ex-4 was determined by intraparenchymal administration of
Ex-4 at a 100 nl volume. A separate group of rats (n = 12), implanted with bilat-
eral mNTS cannula (at the level of the AP), received counterbalanced unilateral
intraparenchymal mNTS injections of Ex-4 (0.025 mg and 0.05 mg in 100 nl) or
aCSF 5 min prior to dark onset. Likewise, rats (n = 5) implanted with DMV
cannula received counterbalanced injections of Ex-4 (0.05 mg in 100 nl) or
aCSF 5 min prior to dark onset. Cumulative chow intake was recorded at 1,
3, 6, and 24 hr.
A separate set of rats (n = 7) received counterbalanced intraparenchymal
injections of Ex-4 (0.025 mg and 0.05 mg in 100 nl) or aCSF into the AP 5 min
prior to dark onset. Again, chow intake was recorded at 1, 3, 6, and 24 hr.
To functionally verify the AP site of injections, at the completion of the
AP-Ex-4 experiment, the same rats received counterbalanced AP administra-
tion of the amylin agonist, sCT at 0.4 mg/100 nl or aCSF 5 min prior to dark
onset. Food intake was recorded at 0.5, 1, 2, and 4 hr post-food presentation.
Dose and time course of food intake recording for the AP sCT experiment was
conducted as reported (Mollet et al., 2004).
Data and Statistical Analyses
Data for each respective study were analyzed separately and expressed as
mean ± SEM. For all experiments, comparisons between treatment means
were analyzed by one- or two-way ANOVAs and, if appropriate, post hoc, pair-
wise comparisons were made using Tukey’s honestly significant difference
test with p < 0.05 considered statistically significant. Analyses were made
using PC-SAS (version 8.02, SAS Institute) mixed procedure.SUPPLEMENTAL INFORMATION
Supplemental Information includes one figure and can be found with this
article at doi:10.1016/j.cmet.2011.02.001.
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